Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results

被引：0
|
作者：
Thomas Semrad
Afsaneh Barzi
Heinz-Josef Lenz
Irene M. Hutchins
Edward J. Kim
I-Yeh Gong
Michael Tanaka
Laurel Beckett
William Holland
Rebekah A. Burich
Leslie Snyder-Solis
Philip Mack
Primo N. Lara
机构：
[1] University of California Davis Comprehensive Cancer Center,Division of Hematology/Oncology, Department of Internal Medicine
[2] University of Southern California Norris Cancer Center,Medical Oncology, Keck School of Medicine
[3] University of California,Department of Internal Medicine
[4] Davis,Division of Biostatistics, Department of Public Health Sciences
[5] University of California,undefined
[6] Davis,undefined
来源：
International Journal of Clinical Oncology | 2015年 / 20卷
关键词：
Gemcitabine; Erlotinib; Pancreatic cancer; Pharmacodynamic separation; KRAS mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：518 / 524
页数：6
相关论文
共 50 条
  • [41] A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer
    Song, Hong Suk
    Do, Young Rok
    Chang, Heung Moon
    Ryu, Min Hee
    Lee, Kyung Hee
    Kim, Yeul Hong
    Hong, Dae Sik
    Cho, Jae Yong
    Lee, Kyoung Eun
    Kim, Si Young
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (05) : 763 - 768
  • [42] Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
    Kulke, Matthew H.
    Blaszkowsky, Lawrence S.
    Ryan, David P.
    Clark, Jeffrey W.
    Meyerhardt, Jeffrey A.
    Zhu, Andrew X.
    Enzinger, Peter C.
    Kwak, Eunice L.
    Muzikansky, Alona
    Lawrence, Colleen
    Fuchs, Charles S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4787 - 4792
  • [43] Is it cost-effective to add erlotinib to gemcitabine in advanced pancreatic cancer?
    Grubbs, S. S.
    Grusenmeyer, P. A.
    Petrelli, N. J.
    Gralla, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 313S - 313S
  • [44] A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer
    Renouf, D. J.
    Tang, P. A.
    Hedley, D.
    Chen, E.
    Kamel-Reid, S.
    Tsao, M. S.
    Tran-Thanh, D.
    Gill, S.
    Dhani, N.
    Au, H. J.
    Wang, L.
    Moore, M. J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (11) : 1909 - 1915
  • [45] A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
    Bassel Fuad El-Rayes
    Philip A. Philip
    Fazlul H. Sarkar
    Anthony F. Shields
    Ann Marie Ferris
    Kenneth Hess
    Ahmad O. Kaseb
    Milind M. Javle
    Gauri R. Varadhachary
    Robert A. Wolff
    James L. Abbruzzese
    Investigational New Drugs, 2011, 29 : 694 - 699
  • [46] FG-3019, a human monoclonal antibody to CTGF, with gemcitabine/erlotinib in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma
    Picozzi, Vincent J.
    Pipas, J. Marc
    Koong, Albert
    Giaccia, Amato
    Bahary, Nathan
    Krishnamurthi, Smitha S.
    Lopez, Charles D.
    O'Dwyer, Peter J.
    Modelska, Katharina
    Poolman, Vanessa
    Chou, James
    Zhong, Ming
    Porter, Seth
    Neff, Tom
    Valone, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [47] A phase 1/2 study of combination therapy of ivaltinostat, gemcitabine, and erlotinib in patients with unresectable, locally advanced and metastatic pancreatic adenocarcinoma
    Jo, J.
    Lee, H.
    Park, S.
    Chung, D.
    Cho, S.
    Cha, H.
    Cho, J.
    Song, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S211 - S211
  • [48] A phase II randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib, and metformin in patients with locally advanced or metastatic pancreatic cancer.
    Wilmink, Johanna
    Kordes, Sil
    Zwinderman, Koos
    Mathot, Ron
    Punt, Cornelis J. A.
    Richel, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
    El-Rayes, Bassel Fuad
    Philip, Philip A.
    Sarkar, Fazlul H.
    Shields, Anthony F.
    Ferris, Ann Marie
    Hess, Kenneth
    Kaseb, Ahmad O.
    Javle, Milind M.
    Varadhachary, Gauri R.
    Wolff, Robert A.
    Abbruzzese, James L.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (04) : 694 - 699
  • [50] FOLFIRINOX in locally advanced or metastatic pancreatic cancer
    Faris, Jason Edward
    Hong, Theodore S.
    McDermott, Shaunagh
    Guimaraes, Alexander R.
    Sahani, Dushyant
    Clark, Jeffrey W.
    Ryan, David P.
    Blaszkowsky, Lawrence Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345